|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Orbit determination and time synchronization for a GEO/IGSO satellite navigation constellation with regional tracking network显示文摘Aiming at regional services,the space segment of COMPASS (Phase I) satellite navigation system is a constellation of Geostationary Earth Orbit (GEO),Inclined Geostationary Earth Orbit (IGSO) and Medium Earth Orbit (MEO) satellites.Precise orbit determination (POD) for the satellites is limited by the geographic distribution of regional tracking stations.Independent time synchronization (TS) system is developed to supplement the regional tracking network,and satellite clock errors and orbit data may be obtained by simultaneously processing both tracking data and TS data.Consequently,inconsistency between tracking system and TS system caused by remaining instrumental errors not calibrated may decrease navigation accuracy.On the other hand,POD for the mixed constellation of GEO/IGSO/MEO with the regional tracking network leads to parameter estimations that are highly correlated.Notorious example of correlation is found between GEO's orbital elements and its clock errors.We estimate orbital elements and clock errors for a 3GEO+2IGSO constellation in this study using a multi-satellite precise orbit determination (MPOD) strategy,with which clock error elimination algorithm is applied to separate orbital and clock estimates to improve numerical efficiency.Satellite Laser Ranging (SLR) data are used to evaluate User Ranging Error (URE),which is the orbital error projected on a receiver's line-of-sight direction.Two-way radio-wave time transfer measurements are used to evaluate clock errors.Experimenting with data from the regional tracking network,we conclude that the fitting of code data is better than 1 m in terms of Root-Mean-Square (RMS),and fitting of carrier phase is better than 1 cm.For orbital evaluation,difference between computed receiver-satellite ranging based on estimated orbits and SLR measurements is better than 1 m (RMS).For clock estimates evaluation,2-hour linear-fitting shows that the satellite clock rates are about 1.E-10 s/s,while receiver clock rates are about 1×10 13-1×10 12 s/s.For the 72-hour POD experiment,the average differences between POD satellite clock rates estimates and clock measurements based on TS system are about 1×10 13 s/s,and for receiver clock rates,the differences are about 1×10 15 s/s. | ZHOU ShanShi HU XiaoGong WU Bin LIU Li QU WeiJing GUO Rui HE Feng CAO YueLing Wu XiaoLi ZHU LingFeng SHI Xin TAN HongLi | 2011 | Science China(Physics,Mechanics & Astronomy)2011，54，6： | 44 |
| 2 | Green‑Solvent Processed Blade‑Coating Organic Solar Cells with an Efficiency Approaching 19%Enabled by Alkyl‑Tailored Acceptors显示文摘Power-conversion-efficiencies(PCEs)of organic solar cells(OSCs)in laboratory,normally processed by spin-coating technology with toxic halogenated solvents,have reached over 19%.However,there is usually a marked PCE drop when the bladecoating and/or green-solvents toward large-scale printing are used instead,which hampers the practical development of OSCs.Here,a new series of N-alkyl-tailored small molecule acceptors named YR-SeNF with a same molecular main backbone are developed by combining selenium-fused central-core and naphthalene-fused endgroup.Thanks to the N-alkyl engineering,NIR-absorbing YR-SeNF series show different crystallinity,packing patterns,and miscibility with polymeric donor.The studies exhibit that the molecular packing,crystallinity,and vertical distribution of active layer morphologies are well optimized by introducing newly designed guest acceptor associated with tailored N-alkyl chains,providing the improved charge transfer dynamics and stability for the PM6:L8-BO:YRSeNF-based OSCs.As a result,a record-high PCE approaching 19%is achieved in the blade-coating OSCs fabricated from a greensolvent o-xylene with high-boiling point.Notably,ternary OSCs offer robust operating stability under maximum-power-point tracking and well-keep>80%of the initial PCEs for even over 400 h.Our alkyl-tailored guest acceptor strategy provides a unique approach to develop green-solvent and blade-coating processed high-efficiency and operating stable OSCs,which paves a way for industrial development. | Hairui Bai Ruijie Ma Wenyan Su Top Archie Dela Pea Tengfei Li Lingxiao Tang Jie Yang Bin Hu Yilin Wang Zhaozhao Bi Yueling Su Qi Wei Qiang Wu Yuwei Duan Yuxiang Li Jiaying Wu Zicheng Ding Xunfan Liao Yinjuan Huang Chao Gao Guanghao Lu Mingjie Li Weiguo Zhu Gang Li Qunping Fan Wei Ma | 2023 | Nano-Micro Letters2023，15，12： | 1 |
| 3 | The Research Progression of Calcitonin for the Therapy of Renal Osteodystrophy显示文摘Calcitonin is a common medicine used in the treatment of osteoporosis,which could restrain the activity of osteoclasts,stop the loss of osteocalcin and reduce the transfer of osteocalcin.Calcitonin can also be used in the treatment of the pain-caused diseases which usually cause by hypercalcemia and others such like Paget's disease and bone tumors.As is approved by several clinic researches,calcitonin is powerful in adjusting the level of calcium,phosphorus and PTH during the treatment of renal osteodystrophy.In addition,it could improves the life quality of the patients who suffered from chronic kidney disease(CKD)and extending their life period.At present,several studies have shown us Calcitonin could be treated in renal osteodystrophy.However,the treatment experiences of Calcitonin are still lacking.Better understanding of the clinical evaluation for calcitonin in the treatment of renal osteodystrophy will hopefully help us to improve outcomes for these patients. | Yingyan LI Sibo HUANG Shengling HUANG Shuang CUI Xiangnan DONG Yueling ZHU Baozhang GUAN Taksui WONG Bing YAN Bo HU Xin CHEN Shanshan LI Fanna LIU Huiyuan ZHENG Tong LIU Hongwei HU Shaofeng HUANG Shufei ZENG Chen YUN Wolfgang Pommer Zuhui CHEN Lianghong YIN Berthold Hocher | 2017 | 临床医学工程2017，24，S1： | 0 |
| 4 | The Pathogenesis of the Mechanism of FGF23 in Chronic Kidney Disease Patients with Vascular Calcification显示文摘Fibroblast growth factor 23(FGF23)is a protein synthesized by bone cell and the osteoblast with endocrine function.The main role of FGF23 is to regulate serum phosphorus and 1,25(OH)2 D3 levels,it also plays an important role in calcium and phosphorus metabolism.The role of FGF23 in renal disease is to inhibit of phosphorus reabsorption,promote urinary phosphorus excretion and maintain a stable blood phosphorus level.Patients with chronic kidney disease(CKD)have more risk to suffer cardiovascular disease(CVD)which is related to the abnormal metabolism of calcium and phosphorus.FGF23,as newly discovered cardiovascular risk marker,several studies have shown that FGF23 level associates with multiple cardiovascular risk factors in CKD patients,especially in CKD patients with vascular calcification.To explore its pathogenesis of vascular calcification in CKD patients is particularly important,and that may help to take appropriate measures to improve the prognosis of CKD patients. | Shanshan LI Wenyu GNOG Sibo HUANG Lianghong YIN Bo HU Xiangnan DONG Taksui WONG Fanna LIU Yingyan LI Yueling ZHU Xin CHEN Baozhang GUAN Shengling HUANG Shuang CUI Bing YAN Hongwei HU Shaofeng HUANG Yongpin LU Shufei ZENG Chen YUN Berthold Hocher Wolfgang Pomme | 2017 | 临床医学工程2017，24，S1： | 0 |
| 5 | Progress in the Clinical Application of Cinacalcet in the Treatment of Secondary Hyperthyroidism显示文摘Secondary hyperthyroidism(SHPT)is a common complication of maintenance hemodialysis(MHD).In China the prevalence of chronic kidney disease(CKD)is 10.8%and there are about 0.2 million patients treated with maintenance hemodialysis.These number are still increasing.Cinacalcet is a new calcium sensing receptor agonist to treat SHPT and the first calcimimetics be approved by Food and Drug Administration(FDA)to treat human.It can activate the calcium sensing receptor in parathyroid to improving control of parathyroid hormone(PTH),serum calcium,phosphorus,and calcium phosphorus product.Then decrease vascular calcification and parathyroid gland volume and reduce the occurrence of fracture and calcific uremic arteriolopathy(CUA).A better understanding of the clinical evaluation for Cinacalcet will hopefully help us to reduce the incidence of SHPT. | Yueling ZHU Shengling HUANG Shuang Cui Lianghong YIN Taksui Wong Xiangnan DONG Bing YAN Baozhang GUAN Bo HU Fanna LIU Yingyan LI Shanshan LI Xin CHEN Berthold Hocher Wolfgang Pommer | 2017 | 临床医学工程2017，24，S1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员